Brokers Set Expectations for Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Cytokinetics in a report released on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings of ($1.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.53) EPS and FY2025 earnings at ($5.83) EPS.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The company had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million.

Several other equities research analysts also recently commented on CYTK. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research note on Thursday, February 6th. Royal Bank of Canada boosted their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price objective on the stock. Mizuho lifted their target price on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Finally, Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $82.00.

Cytokinetics Price Performance

Cytokinetics stock opened at $46.00 on Monday. The business has a 50 day simple moving average of $47.22 and a 200 day simple moving average of $51.22. Cytokinetics has a one year low of $40.53 and a one year high of $75.71. The company has a market capitalization of $5.43 billion, a PE ratio of -8.55 and a beta of 0.83. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.

Insider Buying and Selling

In other news, EVP Fady Ibraham Malik sold 7,300 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.64, for a total value of $369,672.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at $5,877,835.44. This trade represents a 5.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Wendall Wierenga sold 742 shares of Cytokinetics stock in a transaction on Monday, December 16th. The stock was sold at an average price of $48.61, for a total value of $36,068.62. Following the sale, the director now directly owns 24,559 shares of the company’s stock, valued at approximately $1,193,812.99. This trade represents a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,822 shares of company stock worth $874,048 over the last three months. 3.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deep Track Capital LP increased its stake in shares of Cytokinetics by 296.9% in the 4th quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $117,600,000 after acquiring an additional 1,870,094 shares during the last quarter. Capital International Investors bought a new stake in Cytokinetics in the fourth quarter valued at approximately $51,564,000. T. Rowe Price Investment Management Inc. increased its stake in Cytokinetics by 11.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company’s stock valued at $505,780,000 after purchasing an additional 1,062,136 shares in the last quarter. Norges Bank acquired a new stake in Cytokinetics in the fourth quarter worth $46,556,000. Finally, Vestal Point Capital LP boosted its position in shares of Cytokinetics by 56.7% during the fourth quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock worth $110,544,000 after purchasing an additional 850,000 shares in the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.